

**RUBRA MEDICAMENTS LIMITED**

**Part I**

**(Rupees in Lacs)**

**Statement of Standalone Audited Results for the Quarter and Year ended 31/03/2016**

Sr. No	Particulars	3 months ended	Preceeding 3 months ended	Corresponding 3 months ended in previous year	Current Year Ended	Previous year Ended
		31-Mar-16	31-Dec-15	31-Mar-15	31-Mar-16	31-Mar-15
		Audited	Unaudited	Unaudited	Audited	Audited
1	Income from operations					
	Net Sales/Income form Operations (Net of Excise Duty)	6.95	6.47	0.00	19.54	0.00
	Other Operating Income	0.00	0.00	0.00	0.00	0.00
	<b>Total Income from Operations (Net)</b>	<b>6.95</b>	<b>6.47</b>	<b>0.00</b>	<b>19.54</b>	<b>0.00</b>
<b>2</b>	<b>Expenses</b>					
a	Cost of Materials Consumed	0.00	0.00	0.00	0.00	0.00
b	Purchases of Stock-in-trade	5.45	5.08	0.00	12.59	0.00
c	Changes in Inventories of finished goods, work-in-progress and stock-in-trade	0.00	0.00	0.42	0.00	0.00
d	Employee Benefit Expense	0.45	0.45	0.00	1.80	0.42
e	Depreciation and amortisation expenses	0.00	0.00	0.00	0.00	0.00
f	Other Expenses (Any item exceeding 10% of the total expenses relating to continuing operators to be shown separately)	0.78	0.69	1.10	5.83	7.06
	<b>Total Expenses</b>	<b>6.68</b>	<b>6.22</b>	<b>1.52</b>	<b>20.22</b>	<b>7.48</b>
3	<b>Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)</b>	<b>0.27</b>	<b>0.25</b>	<b>-1.52</b>	<b>-0.68</b>	<b>-7.48</b>
4	<b>Other Income</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
5	<b>Profit / (Loss) from Ordinary activities before finance costs and exceptional items (3+4)</b>	<b>0.27</b>	<b>0.25</b>	<b>-1.52</b>	<b>-0.68</b>	<b>-7.48</b>
6	Finance Cost	0.00	0.00	0.00	0.00	0.00
7	<b>Profit / (Loss) from Ordinary activities after finance costs but before exceptional items (5+6)</b>	<b>0.27</b>	<b>0.25</b>	<b>-1.52</b>	<b>-0.68</b>	<b>-7.48</b>
8	Exceptional Items	0.00	0.00	0.00	0.00	0.00
9	<b>Profit / (Loss) from Ordinary activities before tax (7+8)</b>	<b>0.27</b>	<b>0.25</b>	<b>-1.52</b>	<b>-0.68</b>	<b>-7.48</b>
10	Tax Expenses	0.00	0.00	0.00	0.00	0.00
11	<b>Profit / (Loss) from Ordinary activities after tax (9+10)</b>	<b>0.27</b>	<b>0.25</b>	<b>-1.52</b>	<b>-0.68</b>	<b>-7.48</b>
12	Extraordinary Items (net of tax expense)	0.00	0.00	0.00	0.00	0.00
13	<b>Net Profit / (Loss) for the period (11+12)</b>	<b>0.27</b>	<b>0.25</b>	<b>-1.52</b>	<b>-0.68</b>	<b>-7.48</b>
14	Share of Profit/(Loss) of associates	0.00	0.00	0.00	0.00	0.00
15	Minority Interest	0.00	0.00	0.00	0.00	0.00
16	Net Profit / (Loss) after taxes, minority interest and share of profit/(loss) of associates (13+14+15)	0.27	0.25	-1.52	-0.68	-7.48
17	Paid-up equity share capital (Face value of the Share is Rs.10/- each)	546.83	546.83	546.83	546.83	546.83
18	Reserves excluding Revaluation Reserves as per balance sheet) of previous accounting year				-508.43	-507.75
19.i	Earnings Per Share (EPS) (before Extraordinary items) of Rs. 10/- each (not to be annualized)					
	a) Basic	0.00	0.00	-0.03	-0.01	-0.14
	b) Diluted	0.00	0.00	-0.03	-0.01	-0.14
19.ii	Earnings Per Share (EPS) (after Extraordinary items) of Rs. 10/- (not to be annualized)					
	a) Basic	0.00	0.00	-0.03	-0.01	-0.14
	b) Diluted	0.00	0.00	-0.03	-0.01	-0.14
	<b>Notes:</b>					
1	The above results have been reviewed by the Audit Committee and taken on Record by the Board of Directors at its meeting held today					
2	The Segment-wise details are not applicable to the company as company has no segments.					

Date: May 25, 2016

Place: Mumbai

**Managing Director**

**RUBRA MEDICAMENTS LIMITED**  
**STATEMENT OF ASSETS AND LIABILITIES**

A	EQUITY AND LIABILITIES	As on March 31, 2016	As on March 31, 2015
<b>1</b>	<b>Shareholders Funds</b>		
	(a) Share Capital	54,683,000	54,683,000
	(b) Reserves and Surplus	(50,842,784)	(50,774,820)
	(c) Money received against share warrants		
	<b>Sub-total - Shareholders' funds</b>	<b>3,840,216</b>	<b>3,908,180</b>
<b>2</b>	<b>Share application money pending allotment</b>	-	-
<b>3</b>	<b>Minority interest</b>	-	-
<b>4</b>	<b>Non-current liabilities</b>		
	(a) Long-term borrowings	-	-
	(b) Deferred tax liabilities (net)	746,257	746,257
	(c) Other long-term liabilities		-
	(d) Long-term provisions		-
	<b>Sub-total - Non-current liabilities</b>	<b>746,257</b>	<b>746,257</b>
<b>5</b>	<b>Current liabilities</b>		
	(a) Short-term borrowings	-	-
	(b) Trade payables	-	-
	(c) Other current liabilities	-	-
	(d) Short-term provisions	-	-
	<b>Sub-total - Current liabilities</b>	-	-
	<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>4,586,473</b>	<b>4,654,437</b>
<b>B</b>	<b>ASSETS</b>		
<b>1</b>	<b>Non-current assets</b>		
	(a) Fixed assets	-	-
	(b) Goodwill on consolidation	-	-
	(c) Non-current investments	-	-
	(d) Deferred tax assets (net)	-	-
	(e) Long-term loans and advances	3,282,070	3,054,070
	(f) Other non-current assets	168,819	168,819
	<b>Sub-total - Non-current assets</b>	<b>3,450,889</b>	<b>3,222,889</b>
<b>2</b>	<b>Current Assets</b>		
	(a) Current investments	-	-
	(b) Inventories	-	-
	(c) Trade receivables	177,269	177,269
	(d) Cash and cash equivalents	958,315	1,254,279
	(e) Short-term loans and advances		-
	(f) Other current assets		-
	<b>Sub-total - Current assets</b>	<b>1,135,584</b>	<b>1,431,548</b>
	<b>TOTAL - ASSETS</b>	<b>4,586,473</b>	<b>4,654,437</b>